Sangamo Therapeutics (NASDAQ:SGMO) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research report sent to investors on Thursday,Benzinga reports. HC Wainwright currently has a $10.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Sangamo Therapeutics’ FY2028 earnings at $0.64 EPS.

A number of other research analysts have also commented on SGMO. Barclays raised their price target on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday. StockNews.com assumed coverage on shares of Sangamo Therapeutics in a research note on Sunday, July 28th. They issued a “sell” rating for the company.

Sangamo Therapeutics Stock Performance

Sangamo Therapeutics stock opened at $2.05 on Thursday. Sangamo Therapeutics has a one year low of $0.30 and a one year high of $3.18. The company has a 50-day simple moving average of $1.33 and a 200-day simple moving average of $0.87. The firm has a market capitalization of $427.73 million, a P/E ratio of -2.73 and a beta of 1.10.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The company had revenue of $49.41 million for the quarter, compared to analysts’ expectations of $26.55 million. During the same quarter in the previous year, the company posted ($0.34) earnings per share. As a group, sell-side analysts forecast that Sangamo Therapeutics will post -0.5 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SGMO. Renaissance Technologies LLC boosted its position in shares of Sangamo Therapeutics by 58.8% during the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock valued at $1,479,000 after purchasing an additional 1,528,600 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Sangamo Therapeutics during the first quarter worth approximately $331,000. Geode Capital Management LLC grew its position in Sangamo Therapeutics by 14.6% in the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock worth $1,853,000 after buying an additional 272,123 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Sangamo Therapeutics in the second quarter valued at $89,000. Finally, Vontobel Holding Ltd. lifted its position in shares of Sangamo Therapeutics by 412.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock valued at $259,000 after acquiring an additional 241,440 shares during the last quarter. 56.93% of the stock is owned by institutional investors and hedge funds.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.